Endo, a global specialty pharmaceutical company focused on branded and generic pharmaceuticals, was formed following the acquisition of Paladin Labs. Revenues from the segment is projected to decline in the high single-to low double-digit percentage range in 2017 due to base business sales decline, partially offset by revenues growth in sterile injectables and new launch in alternative dosages which will be partially offset by growth in its sterile injectables and new launch revenues respectively. Endo’s Branded segment continues to be under pressure due to additional competitive entrants as well as a continuous rise in the number of public policy and regulatory actions including the recent CDC guidelines related to opioid prescribing and use and divestiture of Strenda.
The major market indexes moved higher amid several key central bank speeches Friday. Fed Chair Janet Yellen's speech from Jackson Hole began at 10 a.m. ET. The topic of her speech was financial stability and in early comments she argued firmly against rolling back banking reforms implemented after the 2008 financial crisis. Next up is European Central Bank president Mario Draghi. The ECB is expected to unveil its strategy to wind down its bond buying program over the next few months. All three major indexes — the tech-heavy Nasdaq, S&P 500 and Dow Jones industrial average perked up about 0.5% each. XAutoplay: On | Off Among the Dow industrials, Apple (AAPL) traded 0.7% higher in the stock market
CHAPEL HILL, N.C.—Bad news, Amazon investors: The company’s stock, already down 10% from its late-July high, is likely to decline even further. That’s because of the behavior of Wall Street analysts, whose earnings revisions tend to come in waves. And the vast majority of those revisions recently have been to the downside. This represents a big shift from the situation that prevailed as recently as 12 months ago. In August of last year, for example, 69% of Wall Street analysts who track Amazon AMZN, -0.75% revised upward their estimates of the company’s future earnings per share. Just 17% of analysts issued downward revisions that month. So far this August, in contrast, there have been no upward